Drug Profile

UTL-5g

Alternative Names: UTL 5g

Latest Information Update: 14 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator 21st Century Therapeutics
Developer 21st Century Therapeutics; Chengdu Xin Fanyu Biomedical; Sichuan New Phiaring Bio-medical Science
Class Chemoprotectants; Isoxazoles; Radioprotectives; Small molecules
Mechanism of Action Tumour necrosis factor alpha inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

14 Sep 2023 UTL-5g is still in preclinical trials for Chemotherapy-induced-damage (Prevention) in USA (21st Century Therapeutics, September 2023)
14 Sep 2023 UTL-5g is still in preclinical trials for Radiation-injuries (Prevention) in USA (21st Century Therapeutics, September 2023)
28 Jul 2018 No recent reports of development identified for preclinical development in Sepsis in China

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com